Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases

Mol Ther. 2023 Jan 4;31(1):7-23. doi: 10.1016/j.ymthe.2022.09.017. Epub 2022 Oct 4.

Abstract

Krabbe disease (KD) is a lysosomal storage disease (LSD) caused by mutations in the galc gene. There are over 50 monogenetic LSDs, which largely impede the normal development of children and often lead to premature death. At present, there are no cures for LSDs and the available treatments are generally insufficient, short acting, and not without co-morbidities or long-term side effects. The last 30 years have seen significant advances in our understanding of LSD pathology as well as treatment options. Two gene therapy-based clinical trials, NCT04693598 and NCT04771416, for KD were recently started based on those advances. This review will discuss how our knowledge of KD got to where it is today, focusing on preclinical investigations, and how what was discovered may prove beneficial for the treatment of other LSDs.

Keywords: Krabbe disease; adeno-associated viral vectors; demyelination; lysosomal storage disease; monogenetic diseases; psychosine; substrate reduction therapies.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child
  • Combined Modality Therapy
  • Humans
  • Leukodystrophy, Globoid Cell* / genetics
  • Leukodystrophy, Globoid Cell* / pathology
  • Leukodystrophy, Globoid Cell* / therapy
  • Lysosomal Storage Diseases* / genetics
  • Lysosomal Storage Diseases* / therapy
  • Mutation

Associated data

  • ClinicalTrials.gov/NCT04771416
  • ClinicalTrials.gov/NCT04693598